Increasing the infliximab dose in rheumatoid arthritis patients: a randomized, double blind study failed to confirm its efficacy.

PAVELKA, Karel, Kateřina JAROŠOVÁ, David SUCHÝ, Ladislav ŠENOLD, Karel CHROUST, Ladislav DUŠEK and Jiří VENCOVSKÝ. Increasing the infliximab dose in rheumatoid arthritis patients: a randomized, double blind study failed to confirm its efficacy. Annals of the Rheumatic Diseases. London: BMI Journals, 2009, vol. 68, No 8, 6 pp. ISSN 0003-4967.

Basic information

Original name

Increasing the infliximab dose in rheumatoid arthritis patients: a randomized, double blind study failed to confirm its efficacy.

Name in Czech

Zvýšení dávky Infliximabu u pacientů s revmatoidní artritidou: randomizovaná dvojitě zaslepená studie bez potvrzení účinnosti

Name (in English)

Increasing the infliximab dose in rheumatoid arthritis patients: a randomized, double blind study failed to confirm its efficacy.

Authors

PAVELKA, Karel, Kateřina JAROŠOVÁ, David SUCHÝ, Ladislav ŠENOLD, Karel CHROUST, Ladislav DUŠEK and Jiří VENCOVSKÝ

Edition

Annals of the Rheumatic Diseases, London, BMI Journals, 2009, 0003-4967

---

Other information

Language

Czech

Type of outcome

Článek v odborném periodiku

Field of Study

30000 3. Medical and Health Sciences

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 8.111

Organization unit

Faculty of Medicine

UT WoS

000268010500009

Keywords (in Czech)

revmatoidní artritida; terapie; infliximab; zvýšení dávky

Keywords in English

rheumatoid arthritis; therapy; infliximab; dose escalation

Tags

dose escalation, infliximab, rheumatoid arthritis, THERAPY

---

Abstract

V originále

In this study, increasing the infliximab dose from 3 to 5 mg/kg in RA patients with residual disease activity did not improve efficacy but moderately increased toxicity. These data indicate that a switch to another biological treatment would be a more appropriate strategy in incomplete responders.

In English

In this study, increasing the infliximab dose from 3 to 5 mg/kg in RA patients with residual disease activity did not improve efficacy but moderately increased toxicity. These data indicate that a switch to another biological treatment would be a more appropriate strategy in incomplete responders.